Evidence map›Paper›PMID 41889630›Full record

ArticleFrontiers in public health2026

Epidemiology of

Yifei Duan, Yu Wu, Yu Gou, Xiao-Qin Liu, Zheng-Xiang Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Risk factors for severeFrontiers in pediatrics · 2026
    Article
  2. Characteristics ofFrontiers in pediatrics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yifei DuanDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University. Chengdu, Sichuan, China.
Yu WuDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University. Chengdu, Sichuan, China.
Yu GouDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University. Chengdu, Sichuan, China.
Xiao-Qin LiuDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University. Chengdu, Sichuan, China.
Zheng-Xiang GaoDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University. Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: Children with ARTIs attending the West China Second Hospital of Sichuan University from January 2022 to December 2023 were selected. IgM antibodies against Chlamydia pneumoniae ( Results: Over the two-year period, 20,689 children were included. In 2022, under stringent COVID-19 non-pharmaceutical interventions (NPIs), 453 positive and 10,092 negative cases, with IgM seropositivity rate of 4.3%. In 2023, following the nationwide relaxation of these NPIs, 602 positive cases, and 9,542 negative cases for IgM seropositivity rate of 5.9%, which was significantly higher than that in 2022 ( Conclusion: The results revealed that the epidemic trend and population susceptible to

Indexed as

Chlamydophila InfectionsChlamydophila pneumoniaeRespiratory Tract InfectionsAcute DiseaseAdolescentAntibodies, BacterialChildChild, PreschoolChinaFemaleHumansImmunoglobulin MInfantMaleAntibodies, BacterialImmunoglobulin Macute respiratory tract infectionschildrenChinachlamydia pneumoniaeepidemiology

Identifiers

PMID41889630
PMCPMC13014552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.